| Market Cap | ₹1,10,705 CrLarge Cap |
|---|---|
| Net Profit TTM | ₹5,332 Cr62.5% YoY Growth |
| PE Ratio | 20.76Industry PE 45.68 |
| Day RSI | 50.28Neutral Zone |
Key highlights
- US FDA approval received for Sugammadex Injection in 200 mg/2 mL and 500 mg/5 mL single-dose vials
- Product is bioequivalent to Merck’s Bridion for reversal of rocuronium and vecuronium bromide
- Approved for use in adults and pediatric patients aged 2 years and older undergoing surgery
- Lupin reported a 62.51% growth in annual net profit reaching ₹5,332.84 crore TTM
- The company maintains a strong Durability Score of 80 with a 33.25% operating margin
The Product — What It Is
Sugammadex Injection is a specialized medication designed to reverse neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgical procedures. Lupin's version is available in two strengths: 200 mg/2 mL and 500 mg/5 mL single-dose vials. The product provides a critical function in anesthesia recovery, allowing clinicians to quickly restore muscle function in patients aged two years and older.
As a bioequivalent to the branded Bridion, it offers a generic alternative for a medication frequently utilized in operating rooms across the United States, supporting improved patient throughput in clinical settings.
Commercial Opportunity
- Targets the high-volume US anesthesia and surgical recovery market segment
- Provides a cost-effective generic alternative to Merck’s high-revenue Bridion injection
- Strengthens Lupin's growing portfolio of complex injectable products in North America
- Addresses clinical needs for both adult and pediatric surgical patient populations
- Leverages Lupin's established distribution network reaching over 100 global markets
Strategic Fit
The launch of Sugammadex Injection aligns with Lupin's strategy to expand its complex generics and injectable footprint in the US market. By targeting high-barrier-to-entry therapy areas such as respiratory, cardiovascular, and central nervous system health, the company aims to diversify its revenue streams beyond oral solids. The addition of this product complements Lupin's existing manufacturing infrastructure, which includes 15 state-of-the-art sites and 7 research centers.
This move capitalizes on the increasing demand for affordable surgical recovery solutions while utilizing the company's dedicated workforce of over 26,000 professionals to drive market penetration.
Financial Context
- Consolidated TTM Operating Revenue stands at ₹27,958.03 crore
- Net profit for the latest quarter surged by 89.04% year-over-year to ₹1,460.34 crore
- Promoter holding remains stable at 46.85% with zero percentage of pledged shares
- The stock is trading at a PE of 20.76, significantly below the industry average of 45.68
- Institutional investors maintain a high stake of 47.07% in the company
| Share price | ₹2421.2 |
|---|---|
| Market capitalisation | ₹1.11L Cr |
| Revenue (annual) | ₹27,958.03 Cr |
| Net profit (annual) | ₹5,332.84 Cr |
| Revenue (latest quarter) | ₹7,474.66 Cr+4.29% vs previous quarter |
| Net profit (latest quarter) | ₹1,460.34 Cr+24.23% vs previous quarter |
| P/E (TTM) | 20.76×Sector 45.69× |
| Promoter holding | 46.85%-0.01% QoQ |
| FII holding | 22.42%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Lupin Limited announcing the US FDA approval and commercial launch of Sugammadex Injection. Market figures from a third-party data provider.
